Authors
Loading...
Observational analysis revealed that ornithine decarboxylase deficiency lowers graft-vers-host disease severity in recipients, suggesting a therapeutic advantage for GVL effects.
Zheng et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: